Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Everyday Health on MSN
What Are Your Odds of Getting HIV?
Learn about the risk of getting HIV from anal sex, vaginal sex, oral sex, and shared needles, plus the most effective ways to ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
In the absence of a vaccine, injectable antibodies are currently being tested as a way to prevent HIV infection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback